脑健康与更长的脑内雌激素暴露有关
Brain Health Linked With Longer Lifetime Estrogen Exposure
一项瑞典研究显示,更长的生殖期与较低的脑小血管疾病负担相关。雌激素替代疗法与更好的白质完整性和较少的血管异常相关。雌激素暴露与阿尔茨海默病相关的皮层厚度增加有关。研究结果强调了考虑女性生殖和激素历史的重要性,特别是在研究脑衰老和痴呆风险时。
— Menopausal hormone therapy tied to lower cerebral small vessel disease burden, study shows
by Judy George, Deputy Managing Editor, MedPage Today
November 4, 2026 • 3 min read
- A longer reproductive lifespan was associated with lower cerebral small vessel disease burden in a Swedish study of older women.
- Menopausal hormone therapy correlated with better white matter integrity and fewer vascular abnormalities.
- Among APOE4 carriers, menopausal hormone therapy was associated with greater Alzheimer's-related cortical thickness.
Women with higher lifetime estrogen exposure had less cerebrovascular pathology, a cohort study in Sweden showed.
A longer reproductive span was associated with 8% lower odds of having two or more signs of cerebral small vessel disease (OR 0.92, 95% CI 0.86-0.99), reported Anna Marseglia, PhD, of the Karolinska Institutet in Stockholm, and co-authors.
Menopausal hormone therapy was also linked with lower cerebral small vessel disease burden (OR 0.41, 95% CI 0.20-0.81) and with increasing white matter integrity (ß=0.28, 95% CI 0.06-0.50), Marseglia and colleagues wrote in Neurology.
Among APOE4 carriers only, menopausal hormone therapy was associated with greater cortical thickness in brain regions typically affected by Alzheimer's disease (β=0.38, 95% CI 0.01-0.76).
Women who used oral contraceptives earlier in life and menopausal hormone therapy later had the lowest small vessel disease burden (OR 0.31, 95% CI 0.12-0.83) and the greatest white matter integrity (β=0.45, 95% CI 0.12-0.78), the researchers said.
"What was particularly striking was that the most favorable vascular brain health was observed among women who had used oral contraceptives during their reproductive years and later received menopausal hormone therapy. This suggests that hormonal factors acting across different stages of a woman's life may have cumulative associations with cerebrovascular health in older age," Marseglia said in a statement.
"While these findings do not establish cause and effect, they underscore the importance of considering women's reproductive and hormonal history when studying brain aging and dementia risk, not only in relation to Alzheimer's disease but also to vascular disease," she added.
The role of endogenous and exogenous estrogen exposure in brain health may be an opportunity to identify dementia mechanisms, observed Tracy Madsen, MD, PhD, of the University of Vermont in Burlington.
"The lifetime risk of dementia in U.S. women exceeds that of men, and recent projections suggest that by 2060, the number of incident dementia cases in women will surpass that of men by 233,000," Madsen wrote in an accompanying editorial.
The link between estrogen exposure and brain health has become more important with the FDA's recent removal of its black box warning from menopausal hormone therapy, Madsen pointed out. "Furthermore, the idea of reproductive lifespan and ovarian longevity as a potential modifiable target is a critical concept for women's health," she wrote.
Early research suggested that menopausal hormone therapy might protect against Alzheimer's and cardiovascular disease, but in 2003, the Women's Health Initiative Memory Study (WHIMS) reported that estrogen-plus-progestin formulations increased probable dementia risk in women ages 65 or older. The Women's Health Initiative trial also linked combined estrogen and progestin to higher breast cancer and heart disease risks, leading to black box warnings which the FDA removed in 2026.
Over time, the use of hormone replacement therapy in the U.S. declined among postmenopausal women from 26.9% in 1999 to 4.7% in 2020. The treatment is still considered controversial.
More recently, autopsy data and other research have linked estrogen-only menopausal hormone therapy with reduced Alzheimer's neuropathology and lower odds of a dementia diagnosis. A large U.K. Biobank study also suggested that starting hormone replacement therapy early was associated with a lower risk of Alzheimer's and dementia.
In their study, Marseglia and colleagues assessed 352 cognitively unimpaired women from the 1944 Gothenburg H70 birth cohort study who had brain MRI at age 70. Of these, 286 participated in a follow-up exam 5 years later.
The mean Mini-Mental State Examination (MMSE) score was 29.2 at baseline, indicating normal cognitive function. About one-third (31%) of the cohort were APOE4 carriers.
Reproductive lifespan was calculated by subtracting the age at menarche from the age at menopause or oophorectomy. Study outcomes included cerebral small vessel disease, Alzheimer's-related cortical thickness, and white matter integrity. Small vessel disease burden was a composite score derived from white matter hyperintensities, lacunes, cerebral microbleeds, and perivascular spaces.
On average, women had a reproductive lifespan of 37.1 years. Most women (72.7%) reported using oral contraceptives; 60.8% reported using menopausal hormone therapy.
Longer estrogen exposure was associated with stable cortical thickness and white matter trajectories over time, the researchers said. Use of menopausal hormone therapy was linked with fewer perivascular spaces and cerebral microbleeds, they added.
Hormone exposure was reported by participants and may be subject to recall bias and misclassification, Marseglia and co-authors acknowledged. The study lacked detailed information about oral contraceptive and hormone therapy use.
来源:MedPage Today · medpagetoday.com